RE: Sir John Bell comments9 Jan 2022 08:57
ROCHE???? LFTs????
'Bell has been a non-executive director of Roche since 2001.[15] A BMJ campaign to make the results of unpublished studies on the anti-influenza drug oseltamivir (Tamiflu) available to researchers led to the journal's editor Fiona Godlee urging Bell "as an internationally respected scientist and clinician and a leader of clinical research in the United Kingdom, to bring your influence to bear on your colleagues on Roche's board."[16] Roche subsequently agreed to a wide policy of data transparency in clinical trials. Matthew Thompson and Carl Heneghan wrote in a letter to the journal "...according to Roche's 2011 financial report, John Bell received 390?000 Swiss Francs (£260?450; €322?450; $420?000) last year for his role on the board of directors. What do Roche and its shareholders expect for this level of involvement and remuneration?"[17][18] The House of Commons Science and Technology Committee report on the subject broadly supported the release of more clinical trial data but urged caution on public release of individual patient data.
Bell serves on the Genentech Board in San Francisco, and formerly served on the scientific advisory board of AstraZeneca (1997–2000).[8] He was the founding director of three biotechnology companies,[4][8] including Oxagen, Avidex, and Powderject and is also on the Board of Atopix.
His charity positions include chairing the board of trustees of the Oxford Health Alliance[9] and the science committee of the UK Biobank.[19] He chairs the Global Health Scientific advisory board of the Bill & Melinda Gates Foundation, he is a Trustee of the Rhodes Trust, he sits on the award jury of the Gairdner Foundation, he is a non-executive member of Genomics England, and he is a member of Cancer Research UK. He has advised governments and foundations in Singapore, France, Canada, Sweden, Finland, and Alberta on biomedical research. He is on the Jenner Institute Board and the Gray Institute Board. He is on the advisory Board for the McGill Genomics Institute and the Montreal Neurological Institute, and chairs the advisory board for the Oak Foundation and the Robertson Foundation. He attended the 2013 Bilderberg Conference.[20]
A 2021 feature article by freelance journalist Paul D Thacker in the BMJ stated: “The government and Oxford University’s failure to be open about Bell’s financial ties make[s] it impossible for the public to know what, if any, interests the professor has when influencing key decisions about which of the many covid-19 tests the UK should purchase.”[21]'
Sign In
Follow the stocks
